Under construction – not a live service
Sign in
Taking people in SwedenNo phase

Exposing Newborns Delivered by Cesarean to Maternal Microbiota

Tests exposing cesarean-born newborns to maternal birth canal microbes to study allergy risk.

Plain-language title generated from the registry record
Registry title: Restoration of Microbiota in Neonates

Key facts

Where
Stockholm, SwedenSee the site

Where in Sweden

  • Karolinska InstitutetStockholm, SwedenTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Karolinska Institutet
Trial code
NCT03928431
Record updated
1 July 2025
Original description
The aim of the study is to examine the effect of exposure of cesarean section (CS) delivered neonates to a natural condition of birth, i.e. to the microbiota of the birth canal, on the acquisition of microbial genes during development of the microbiome at multiple body sites, immune system maturation and allergy risk in childhoodRead full original descriptionShow less

Restoration of Microbiota in Neonates - a Randomized Controlled Trial

The aim of the study is to examine the effect of exposure of cesarean section (CS) delivered neonates to a natural condition of birth, i.e. to the microbiota of the birth canal, on the acquisition of microbial genes during development of the microbiome at multiple body sites, immune system maturation and allergy risk in childhood

Inclusion: Infants of healthy mothers with uncomplicated pregnancies at term, mothers of any ethnic or social background that can speak, read, and understand Swedish to the extent that they can consent in Swedish. An additional inclusion criterion for mothers in the CS groups is vaginal pH ≤ 4 at the time of birth.

Exclusion: Infants of mothers with pre-eclampsia or complicated pregnancies, mothers <18 years or >40 years of age, genital herpes simplex, genital warts, HIV, Hepatitis B or complications during delivery, infants delivered prior to 37 weeks of gestation. Additional exclusion criteria for mothers in the CS group: Mothers positive to Group B Streptococcus, Group A Streptococcus, bacterial vaginosis, vaginal pH > 4 at the time of birth. Mothers with fecal samples positive for Salmonella, Shigella, Campylobacter or Yersinia.

ClinicalTrials.gov NCT03928431